MX2023003256A - Dosificacion y administracion de anticuerpos anti-c5 para tratar la glomerulonefritis (gn) mediada por c5, incluyendo la nefritis lupica (nl) y/o la nefropatia por iga (niga). - Google Patents
Dosificacion y administracion de anticuerpos anti-c5 para tratar la glomerulonefritis (gn) mediada por c5, incluyendo la nefritis lupica (nl) y/o la nefropatia por iga (niga).Info
- Publication number
- MX2023003256A MX2023003256A MX2023003256A MX2023003256A MX2023003256A MX 2023003256 A MX2023003256 A MX 2023003256A MX 2023003256 A MX2023003256 A MX 2023003256A MX 2023003256 A MX2023003256 A MX 2023003256A MX 2023003256 A MX2023003256 A MX 2023003256A
- Authority
- MX
- Mexico
- Prior art keywords
- igan
- treating
- nephritis
- antibodies
- dosage
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081182P | 2020-09-21 | 2020-09-21 | |
| PCT/US2021/050590 WO2022060931A1 (en) | 2020-09-21 | 2021-09-16 | Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003256A true MX2023003256A (es) | 2023-04-11 |
Family
ID=78087569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003256A MX2023003256A (es) | 2020-09-21 | 2021-09-16 | Dosificacion y administracion de anticuerpos anti-c5 para tratar la glomerulonefritis (gn) mediada por c5, incluyendo la nefritis lupica (nl) y/o la nefropatia por iga (niga). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230348579A1 (https=) |
| EP (1) | EP4213940A1 (https=) |
| JP (1) | JP2023542521A (https=) |
| KR (1) | KR20230073261A (https=) |
| CN (1) | CN116261569A (https=) |
| AU (1) | AU2021344411A1 (https=) |
| CA (1) | CA3173003A1 (https=) |
| IL (1) | IL301350A (https=) |
| MX (1) | MX2023003256A (https=) |
| WO (1) | WO2022060931A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025166118A1 (en) | 2024-02-02 | 2025-08-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| DK3658184T5 (da) * | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
-
2021
- 2021-09-16 EP EP21790712.0A patent/EP4213940A1/en active Pending
- 2021-09-16 MX MX2023003256A patent/MX2023003256A/es unknown
- 2021-09-16 IL IL301350A patent/IL301350A/en unknown
- 2021-09-16 AU AU2021344411A patent/AU2021344411A1/en active Pending
- 2021-09-16 KR KR1020237012983A patent/KR20230073261A/ko active Pending
- 2021-09-16 WO PCT/US2021/050590 patent/WO2022060931A1/en not_active Ceased
- 2021-09-16 CA CA3173003A patent/CA3173003A1/en active Pending
- 2021-09-16 JP JP2023518165A patent/JP2023542521A/ja active Pending
- 2021-09-16 CN CN202180065892.1A patent/CN116261569A/zh active Pending
- 2021-09-16 US US18/026,698 patent/US20230348579A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542521A (ja) | 2023-10-10 |
| CN116261569A (zh) | 2023-06-13 |
| EP4213940A1 (en) | 2023-07-26 |
| AU2021344411A9 (en) | 2024-09-26 |
| IL301350A (en) | 2023-05-01 |
| AU2021344411A1 (en) | 2023-04-27 |
| KR20230073261A (ko) | 2023-05-25 |
| WO2022060931A1 (en) | 2022-03-24 |
| US20230348579A1 (en) | 2023-11-02 |
| CA3173003A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Craig et al. | C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks–final results of the IMPACT 2 study | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| Madden | From a patient advocate’s perspective: does cancer immunotherapy represent a paradigm shift? | |
| Sanchorawala et al. | Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study | |
| Tan et al. | Delayed facial palsy in Miller Fisher syndrome | |
| Salazar‐Degracia et al. | Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice | |
| Luger et al. | Practical algorithm to inform clinical decision‐making in the topical treatment of atopic dermatitis | |
| MX2023003256A (es) | Dosificacion y administracion de anticuerpos anti-c5 para tratar la glomerulonefritis (gn) mediada por c5, incluyendo la nefritis lupica (nl) y/o la nefropatia por iga (niga). | |
| BRPI0511187A (pt) | método para tratar cáncer em um indivìduo | |
| Saif et al. | Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature | |
| MY209272A (en) | Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors | |
| MX2025004652A (es) | Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos | |
| Lesokhin et al. | Magnetismm-3: an open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma | |
| Yeung et al. | Successful use of secukinumab in pustular psoriasis | |
| Sanchorawala et al. | Safety, tolerability and response rates of daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a Phase II study | |
| MX2023001702A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma). | |
| Polito et al. | Type I allergic reaction to rituximab upon first lifetime exposure: a case report | |
| Nahm et al. | Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: a preliminary report | |
| Cornblath et al. | Safety and tolerability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: results of the ProCID Study | |
| Saxena et al. | POS1128 zetomipzomib (kzr-616) treatment results in clinically meaningful renal responses in patients with lupus nephritis | |
| Yasuda et al. | Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis | |
| Shi et al. | Obinutuzumab for PLA2R-associated membranous nephropathy | |
| Aberumand et al. | Monoclonal antibody treatment of COVID-19 in a pregnant woman with common variable immunodeficiency | |
| MX2023015073A (es) | Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la dermatomiositis (dm). | |
| Barabas et al. | Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique |